title: Use of molecular markers to determine postremission treatment in acute myeloid leukemia with normal cytogenetics.
abstract: Most patients with acute myeloid leukemia can be induced into complete remission, but postremission treatment is required for cure. The choice of postremission therapy in a majority of nonelderly patients, between intensive chemotherapy and allogeneic hematopoietic cell transplantation, is largely determined by the results of conventional cytogenetic analysis. In 45% of patients with a normal karyotype, the presence or absence of specific molecular mutations should be used to determine the prognosis and postremission treatment. In addition, the identification of mutations may indicate a role for targeted intervention, including following transplantation.
authors.affiliation: Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA. Electronic address: Edward.Copelan@carolinashealthcare.org.
authors.forename: Edward A
authors.initials: EA
authors.lastname: Copelan
authors.affiliation: Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA.
authors.forename: Michael R
authors.initials: MR
authors.lastname: Grunwald
authors.affiliation: Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA.
authors.forename: Lawrence J
authors.initials: LJ
authors.lastname: Druhan
authors.affiliation: Levine Cancer Institute, Carolinas HealthCare System, University of North Carolina School of Medicine, Charlotte, NC, USA.
authors.forename: Belinda R
authors.initials: BR
authors.lastname: Avalos
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D020732:Cytogenetic Analysis; D006801:Humans; D007621:Karyotyping; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000628:therapy*; D009154:Mutation / Q000235:genetics; D012074:Remission Induction
chemical_list: D014408:Biomarkers, Tumor
keywords: Acute myeloid leukemia; Cytogenetics; Molecular markers